The CD4+AT2R+ T cell subpopulation improves post-infarction remodelling and restores cardiac function

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 8, 2015, Pages 1975-1985

  Skorska, Anna ^a   von Haehling, Stephan ^b,c   Ludwig, Marion ^a   Lux, Cornelia A ^a   Gaebel, Ralf ^a   Kleiner, Gabriela ^a   Klopsch, Christian ^a   Dong, Jun ^d   Curato, Caterina ^b   Altarche Xifró, Wassim ^b   Slavic, Svetlana ^b   Unger, Thomas ^b   Steinhoff, Gustav ^a   Li, Jun ^a,e   David, Robert ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d German Rheumatism Research Centre   (Germany)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin II type 2 receptor; CD4+ lymphocytes; Heart failure cardiac remodelling; Myocardial infarction; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; CARDIOTONIC AGENT; TUMOR NECROSIS FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL TRANSPLANTATION; CONTROLLED STUDY; ENGRAFTMENT; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEART PERFORMANCE; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPLEEN INFARCTION; ANIMAL; BLOOD; COMPLICATION; HEART FUNCTION TEST; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; PATHOPHYSIOLOGY; WISTAR RAT;

RATTUS; RODENTIA;

ANIMALS; CARDIOTONIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; IMMUNOMODULATION; INTERLEUKIN-10; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 2; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR REMODELING;

EID: 84938211163     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12574     Document Type: Article

References (33)

1. Braunwald E. Heart failure. JACC Heart Fail. 2013; 1: 1-20.
2. Pfeffer MA, Pfeffer JM, Fishbein MC, et al. Myocardial infarct size and ventricular function in rats. Circ Res. 1979; 44: 503-12.
3. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc Res. 1998; 39: 89-105.
4. Halapas A, Papalois A, Stauropoulou A, et al. In vivo models for heart failure research. Vivo Athens Greece. 2008; 22: 767-80.
5. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. Animal models of cardiovascular diseases. J Biomed Biotechnol. 2011; 2011: 497841.
6. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol. 1991; 68: 1D-6D.
7. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart Br Card Soc. 2000; 83: 76-80.
8. Xu J, Carretero OA, Lin C-X, et al. Role of cardiac overexpression of ANG II in the regulation of cardiac function and remodeling postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2007; 293: H1900-7.
9. De Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000; 52: 415-72.
10. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000; 52: 639-72.
11. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension. 2010; 55: 924-31.
12. Wu L, Iwai M, Li Z, et al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol. 2004; 18: 666-78.
13. Kaschina E, Grzesiak A, Li J, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation. 2008; 118: 2523-32.
14. Dandapat A, Hu CP, Chen J, et al. Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochem Biophys Res Commun. 2008; 366: 871-7.
15. Li J, Culman J, Hörtnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J. 2005; 19: 617-9.
16. Piqueras L, Kubes P, Alvarez A, et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 2000; 102: 2118-23.
17. + cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells. 2009; 27: 2488-97.
18. + T cell population in response to ischemic heart injury. J Immunol. 2010; 185: 6286-93.
19. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007; 204: 2499-60.
20. Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009; 119: 2904-12.
21. Gaebel R, Furlani D, Sorg H, et al. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS ONE. 2011; 6: e15652.
22. DeGrendele HC, Estess P, Siegelman MH. Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science. 1997; 278: 672-5.
23. Côté F, Do TH, Laflamme L, et al. Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J Biol Chem. 1999; 274: 31686-92.
24. + regulatory T cells. J Immunol. 2005; 174: 6993-7005.
25. Huebener P, Abou-Khamis T, Zymek P, et al. CD44 is critically involved in infarct healing by regulating the inflammatory and fibrotic response. J Immunol. 2008; 180: 2625-33.
26. Tone Y, Furuuchi K, Kojima Y, et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008; 9: 194-202.
27. +CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol Biochem. 2010; 25: 451-8.
28. Tang T-T, Yuan J, Zhu Z-F, et al. Regulatory T cells ameliorate cardiac remodeling after myocardial infarction. Basic Res Cardiol. 2012; 107: 232.
29. Hara M, Kingsley CI, Niimi M, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001; 166: 3789-96.
30. Schottelius AJ, Mayo MW, Sartor RB, et al. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem. 1999; 274: 31868-74.
31. + splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol. 2002; 169: 2461-5.
32. + regulatory cells within the central nervous system. J Immunol. 2005; 175: 3025-32.
33. Namsolleck P, Recarti C, Foulquier S, et al. AT(2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep. 2014; 16: 416.